SOHO ANNUAL MEETING 2024

REAL-WORLD EFFICACY AND TOXICITY OF THE LMBA02 PROTOCOL FOR BURKITT LYMPHOMA IN MOROCCO

Sophia Berrada 1 , Sarah Naim1, Samira Benayad 2, Amine Benmoussa1, Mouna Lamchahab1, Rachid Mohamed1, Abdellah Madani1, Qachouh Meryem1

1. Haematology, Hôpital 20 Août 1953, Casablanca, MAR 2. Pathology, CHU Ibn Rochd, Casablanca, MAR

IBN ROCHD ابن رشد Casablanca الدار البيضاء CHU

INTRODUCTION

Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma that accounts for 1 to 5% of cases in Western Europe. In France, the LMBA02 protocol has shown promising overall survival (OS) and event-free survival (EFS) rates, with 83% and 75% respectively, for patients receiving rituximab. In Morocco, the LMBA02 regimen is used for BL treatment.

AIM

Analyze the real-world **efficacy** and **toxicity** of the LMBA02 protocol in daily clinical practice.

METHOD

Duration : 6 years, from January 2014 to December 2020

Inclusion Criteria:

- Adults > 18 years old with Burkitt lymphoma diagnosed by histological and/or cytological examination according to the new WHO classification.
- Patients treated according to the LMBA 02 protocol.

Data Collection: from patients' medical records.

Statistical Analysis: Overall survival and event-free survival were analyzed using the Kaplan-Meier method with SPSS software.


An event is defined as therapeutic failure, relapse, or death.

RESULTS


1. Patients caracteristics

	n = 63	%
Age, yr		
• 40	39	62
• 40-59	17	27
• > 60	7	11
Sex:		
• Male	45	71
• Female	18	29
ECOG		
• 0 - 1	47	75
• 2 – 4	16	25
Tumor size		
• < 5 cm	19	30
• 5-10 cm	25	40
• > 10 cm	19	30
Advanced stage		
• Yes	29	46
• No	34	54
B symptoms		
• Yes	41	65
• No	22	35
Bone Marrow involvement		
• Yes	12	20
• No	51	80
CNS involvement		
• Yes	8	13
• No	55	87
LDH		
• Normal	28	45
• 1.5 - 2.5 ULN	25	39
• > 2.5 ULN	10	16

2. Survival analysis



(A) OS: 69% (B) EFS: 54%



3. Multivariate analysis according to prognosis factors

Variable	OS			EFS		
	HR	IC (95%)	P	HR	IC	P
Age >40 years	1.3	0.5-3.3	0.5	0.9	0.42-2.2	0.9
No Rituximab	7	1.5-31	0.01	5.2	1.7-15	0.03
LDH >2.5N	4.3	1.3-13.9	0.01	3.7	1.5-9.5	0.05
Group C	2.7	1.0-6.9	0.03	2.5	1.2-6.3	0.01
PS > 2	1.3	0.4-4.1	0.6	0.7	0.31-1.8	0.5

4. Toxicity of LMBA02

Main Complications:

Myelosuppression especially during the COPADM and CYVE courses. Around 82% of patients experienced febrile neutropenia requiring intravenous antibiotics, and 50% required transfusions.

Mucositis was observed in 15% and 6% of patients during the COPADM and CYM/CYVE courses, respectively.

Treatment-related mortality rate (TRM)

11 patients died due to treatment toxicity, resulting in a treatment-related mortality rate (TRM) of 19%. Most deaths occurred during the COPADM treatment phase

CONCLUSIONS

We report here an interesting study that showed the real life experience of patients treated with Burkitt lymphoma using the LMBA02 regimen in a low income country. Key findings from this analysis included identification of similar survival rates in adults with BL compared with prior real life studies, high TRM rate, and significant survival benefit with rituximab

REFERENCES

1.Oosten LEM, Chamuleau MED, Thielen FW, and al.: Treatment of sporadic Burkitt lymphoma in adults, aretrospective comparison of four treatment regimens. Ann Hematol. 2018, 97:255-266. 10.1007/s00277-017-3167-712

2.Castillo JJ, Winer ES, Olszewski AJ: Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013,119:3672-3679. 10.1002/cncr.2826416.

.

CONTACT INFORMATION

Pr S. Berrada, MD hematology
Ber.sophia@gmail.com
Hôpital 20 Août 1953, CHU Ibn Rochd, Casablanca, Morocco
00212 667 806 990